Stock Track | Iovance Biotherapeutics Soars 12.04% Intraday on Multiple Analyst Upgrades and Target Price Increases

Stock Track02-25

Iovance Biotherapeutics, Inc. (IOVA) experienced a significant intraday surge of 12.04% on Wednesday, reflecting strong investor interest in the biotechnology company during the regular trading session.

The sharp increase appears to be driven by a series of positive analyst actions. Barclays maintained a Buy rating on the stock and raised its price target from $10 to $11. Additionally, Citizens upgraded Iovance Biotherapeutics from Market Perform to Market Outperform and set a price target of $5. Baird also raised its price target from $3 to $4, though it maintained a Neutral rating on the shares.

These analyst endorsements and target price increases likely boosted investor confidence in the company's prospects, contributing to the substantial stock price appreciation during the trading day.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1113885710?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-25 23:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1113885710","market":"sg","top_or_hot":-1,"title":"Stock Track | Iovance Biotherapeutics Soars 12.04% Intraday on Multiple Analyst Upgrades and Target Price Increases","media":"Stock Track","content":"<p>Iovance Biotherapeutics, Inc. (IOVA) experienced a significant intraday surge of 12.04% on Wednesday, reflecting strong investor interest in the biotechnology company during the regular trading session.</p><p>The sharp increase appears to be driven by a series of positive analyst actions. Barclays maintained a Buy rating on the stock and raised its price target from $10 to $11. Additionally, Citizens upgraded Iovance Biotherapeutics from Market Perform to Market Outperform and set a price target of $5. Baird also raised its price target from $3 to $4, though it maintained a Neutral rating on the shares.</p><p>These analyst endorsements and target price increases likely boosted investor confidence in the company's prospects, contributing to the substantial stock price appreciation during the trading day.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Iovance Biotherapeutics Soars 12.04% Intraday on Multiple Analyst Upgrades and Target Price Increases</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Iovance Biotherapeutics Soars 12.04% Intraday on Multiple Analyst Upgrades and Target Price Increases\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-25 23:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Iovance Biotherapeutics, Inc. (IOVA) experienced a significant intraday surge of 12.04% on Wednesday, reflecting strong investor interest in the biotechnology company during the regular trading session.</p><p>The sharp increase appears to be driven by a series of positive analyst actions. Barclays maintained a Buy rating on the stock and raised its price target from $10 to $11. Additionally, Citizens upgraded Iovance Biotherapeutics from Market Perform to Market Outperform and set a price target of $5. Baird also raised its price target from $3 to $4, though it maintained a Neutral rating on the shares.</p><p>These analyst endorsements and target price increases likely boosted investor confidence in the company's prospects, contributing to the substantial stock price appreciation during the trading day.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IOVA","symbol_name":"Iovance Biotherapeutics, Inc.","start_time":0,"source_url":"","article_id":"1113885710","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1113885710","pubTimestamp":1772032044,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Iovance Biotherapeutics, Inc. (IOVA) experienced a significant intraday surge of 12.04% on Wednesday, reflecting strong investor interest in the biotechnology company during the regular trading...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IOVA":"Iovance Biotherapeutics, Inc."},"translate_title":"个股追踪|Iovance Biotherapeutics盘中大涨12.04%，多位分析师上调目标价","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IOVA":1},"content_text":"Iovance Biotherapeutics, Inc. (IOVA) experienced a significant intraday surge of 12.04% on Wednesday, reflecting strong investor interest in the biotechnology company during the regular trading session.The sharp increase appears to be driven by a series of positive analyst actions. Barclays maintained a Buy rating on the stock and raised its price target from $10 to $11. Additionally, Citizens upgraded Iovance Biotherapeutics from Market Perform to Market Outperform and set a price target of $5. Baird also raised its price target from $3 to $4, though it maintained a Neutral rating on the shares.These analyst endorsements and target price increases likely boosted investor confidence in the company's prospects, contributing to the substantial stock price appreciation during the trading day.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1113885710","isCrawlerRequest":true}